Therapeutic effect and safety of taxane combined with fluorouracil as first-line chemotherapy in combined modality therapy of esophageal cancer

doi:10.3969/j.issn.1002-7386.2017.10.006

Abstract：Objective To investigate the therapeutic effect and hematological toxicity of taxane combined with fluorouracil as first-line chemotherapy in combined modality therapy of esophageal cancer.Methods The clinical data about 40 patients who were newly diagnosed or postoperatively recurred in our hospital from November 2011 to December 2014 were retrospectively analyzed.These patients were treated by taxane combined with fluorouracil or and its derivant.The therapeutic effect and hematological toxicity were observed and analyzed.Results The response rate (RR) and disease control rate was 57.50% and 90.00%,respectively in all the 40 patients (CR 2cases,PR 21 cases,SD 13 cases and PD 4 cases).Among 40 patients,11 patients received chemotherapy only,and the RR and disease control rate was 27.27% and 81.82%,respectively.The hematologic toxicity was mainly neutropenia,with the incidence rate of grade Ⅲ/Ⅳ neutropenia being 18.18%,and the other 29 patients received concurrent chemoradiotherapy.After treatment,RR and disease control rate was 68.97% and 93.10%,respectively.The main hematologic toxicity was neutropenia,with the incidence rate of grade Ⅲ/Ⅳ neutropenia being 24.14%.Among the 29 patients receiving chemoradiotherapy,16 patients received concurrent chemoradiotherapy and 13 patients received induction chemotherapy before chemoradiotherapy.As compared with the patients in induction chemotherapy group,the patients in concurrent chemoradiotherapy group had higher effective rate and CR rate,however,there were no significant differences between the two groups (P>0.05).Furthermore,there were no significant differences in hematologic toxicities between the two groups (P>0.05).Conclusion The taxane combined with fluorouracil is effective and safe in the first line chemotherapy of esophageal cancer,which is worthy researching further.